Compare
AbbVie vs Regeneron Pharmaceuticals (ABBV vs REGN)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Regeneron Pharmaceuticals (REGN) +40.4%; so far this year the figures are +27.5% and +17.2%.
AbbVie is the larger company by market value, about 5.4 times the size of Regeneron Pharmaceuticals.
On trailing earnings, ABBV trades at 50.1 times and REGN at 20.0 times.
Revenue grew +10.7% at ABBV and +18.6% at REGN over the last year.
ABBV yields 2.38%. REGN yields 0.41%.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | REGN | |
|---|---|---|
| Price | $291.31 | $904.35 |
| 1-day | +1.07% | +0.16% |
| YTD | +27.49% | +17.16% |
| 1 year | +34.39% | +40.39% |
| 3 years | +104.47% | +14.29% |
| Market cap | $514.9B | $95.5B |
| P/E | 50.1 | 20.0 |
| P/S | 7.80 | 5.65 |
| P/B | — | 2.85 |
| Revenue growth | +10.70% | +18.60% |
| EPS growth | +340.20% | +8.30% |
| Gross margin % | 73.7 | 36.4 |
| Net margin % | 15.7 | 28.5 |
| ROE % | — | 14.4 |
| Debt / equity | — | 0.10 |
| FCF yield % | 3.7 | 4.0 |
| Dividend yield % | 2.38 | 0.41 |
| Beta | -0.03 | 0.29 |
| RSI (14) | 59.7 | 63.1 |
| Technical rating |